ENDuodenal cancer is a malignant tumour of the duodenum, the short first stretch of small bowel after the stomach, where the pancreatic and bile ducts open. Tumours here are rare, which is exactly why the diagnosis is often not made the first time round.
Duodenal cancer treatment in Germany takes place not in a separate “rare tumour department” but in large centres for abdominal surgery and oncology that have seen such cases. Below: diagnosis, possible operations and what is added to surgery.
Why this diagnosis is easy to mistake
The complaints are non-specific: heaviness and pain after eating, nausea, vomiting, weight loss, anaemia from hidden blood loss and sometimes jaundice, if the tumour blocks the bile duct outlet. All of this gets treated as gastritis or an ulcer for years.
By location, it is confused with a tumour at the stomach outlet, in the head of the pancreas or in the area of the major duodenal papilla, where the ducts open. Telling them apart matters: the extent of the operation depends on it. The neighbouring topics are stomach cancer treatment in Germany and pancreatic cancer treatment in Germany.
By cell type, adenocarcinomas are not the only tumours here: neuroendocrine tumours, from hormone-producing cells, and GIST, a tumour arising from cells in the bowel wall, also occur and are treated entirely differently. Hence the rule: an exact histology report before treatment starts and, with a rare diagnosis, a review of it.
How the diagnosis is confirmed in a German hospital
Endoscopy is the basis. The stomach and duodenum are inspected with a gastroscope and biopsies are taken from several points; where a papillary tumour is suspected, a side-viewing endoscope is used, because a forward-viewing gastroscope shows the papilla poorly. More on the examination: gastroscopy in Germany.
Next comes the spread. Endoscopic ultrasound shows the depth of growth and nearby lymph nodes; CT and MRI with contrast show how the tumour relates to the vessels and ducts; for a neuroendocrine tumour, a special scan with labelled tracers that collect in its cells is added. These images decide whether the tumour can be removed whole.
Finally, a German pathologist reviews the slides and a tumour board discusses the case. With rare tumours this is not a formality: the diagnosis changes more often than with common ones. The Cancer Information Service of the German Cancer Research Center (in German) counts small bowel tumours among rare cancers and points to hospitals that have treated patients in the same situation.
Surgery: from local removal to a major resection
It depends on where the tumour sits and what it is. Small early tumours are sometimes removed through the endoscope or by cutting out a patch of the wall; this is far from always possible and is decided by depth and cell type.
For an adenocarcinoma, the main option is a pancreaticoduodenectomy: removal of the first part of the bowel with the head of the pancreas and the lymph nodes. “Just the bowel” cannot be taken out: it wraps around the head of the pancreas, both share their blood supply, and the bile and pancreatic ducts run through the head into the bowel.
Other situations: a tumour further from the papilla may need only a segmental resection; a GIST is removed as a nodule, without a wide resection; and if the tumour cannot be removed but food will not pass, an operation restores the passage. If it has grown into the vessels, drug treatment before surgery is discussed.
What is added to surgery
That depends on the tumour type. For an adenocarcinoma, chemotherapy after the operation is usually discussed, and the tumour board decides on the pathologist’s report: the cell type, the resection margins and the lymph nodes. The course is chosen individually.
For other types the logic differs. Neuroendocrine tumours that have spread or produce hormones are treated with drugs that suppress hormone activity, somatostatin analogues, and with targeted agents; GIST with a significant risk of recurrence or with metastases gets targeted therapy according to molecular testing. This analysis of the removed tumour is done as a matter of course in Germany: it shows whether a drug exists that acts on this particular tumour. See also small bowel cancer treatment in Germany.
Where it is treated in Germany and why the centre’s experience matters
It is treated where the pancreas is operated on regularly, as operations in this area count as high-complexity surgery. One of AlenMed’s partners is the Rechts der Isar hospital in Munich, whose surgical clinic is headed by Prof. Helmut Friess; his fields are pancreatic and abdominal surgery, including operations on the oesophagus, liver, bowel and bile ducts.
For the patient, this means the surgeon, endoscopist, pathologist and oncologist discuss the case together, and with a rare tumour it is this joint discussion that most often changes the plan. The final decision and timing come from the hospital.
Frequently asked questions
Can duodenal cancer be cured?
Yes, if the tumour can be removed completely before it spreads to distant organs; small early tumours are sometimes even taken out through the endoscope. Otherwise, treatment aims to control the disease and keep eating possible. A doctor judges the outlook from histology and scans.
Must part of the pancreas always be removed?
No. The head of the pancreas is removed with the bowel mainly for an adenocarcinoma near the papilla, as these organs share vessels and ducts. A tumour further away may need only a stretch of bowel removed, and a GIST only its nodule.
Do I need a new biopsy in Germany?
Not necessarily. A German pathologist first reviews the slides and paraffin blocks you send; new sections and molecular tests can be made from the blocks. A repeat endoscopy with biopsy is suggested only if the tissue is insufficient or the tumour type unclear.
How AlenMed arranges the treatment
AlenMed sends the department the endoscopy report, slides or blocks for review, CT and MRI discs, blood counts, liver function tests and discharge letters. The department answers whether it takes the case, whether a repeat biopsy is needed and how long the trip will take; if it does, the hospital sends a written estimate, the visa invitation is issued, tests are booked back to back and an interpreter attends the consultations (see arranging treatment in Germany).
Before leaving, decide who will accompany you, allow extra time for the histology review and agree with your doctor at home who will continue treatment.
This material is for information and is not an offer; the treatment approach is decided by a doctor in person.
News on this topic
Charité treats first beta-thalassemia patient with CRISPR
At Berlin Charité, a 19-year-old beta-thalassemia patient became the first in Germany to receive the newly approved CRISPR gene therapy Exagamglogene Autotemcel.
Real-World Breast Cancer Study Confirms High Five-Year Survival Rates in Germany
A landmark study of over 43,000 German patients reveals a five-year invasive disease-free survival rate of 82.9 percent in early hormone receptor-positive breast cancer.
FDA Approves Jülich Diagnostic Radiotracer FET for Brain Tumor Imaging
The FDA approves the diagnostic radiotracer FET (Pixclara®) for evaluating brain gliomas, highlighting decades of neuro-oncology research at Forschungszentrum Jülich.
